entertainment -WSS

entertainment

author：focus 2025-09-06 01:21:42 - browse：59227

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： WuXi Biologics beefs up its lobbying operation

WSS

ALS treatment from Biogen, Ionis fails in study

Novo Nordisk testing Wegovy against alcohol

WuXi Biologics beefs up its lobbying operation

Palantir health business leans on meeting customers’ needs

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Oak Street deal isn't the answer to health care's woes

focus

entertainment

hotspot

Peter Hotez and the public health issue of online harassment

WuXi Biologics beefs up its lobbying operation

New air purifier tech could be key to improving indoor air quality

Study: Pain burden is higher in Black NFL players than white ones

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Medicare details structure of new drug price negotiation program

The White House hikes tariffs on plastic syringes made in China

After affirmative action ruling, medical educators look to 'holistic review'

Ripples from Flovent's discontinuation is killing children with asthma

hotspot

NIH fellows want a pay raise. Will that mean less money for grants?

Beach reads and more: STAT's 2023 summer book list

How the political right came to back psychedelics to treat trauma

HCA discloses massive data breach affecting 11 million patients

Palantir health business leans on meeting customers’ needs

Obesity drug from Roche shows promise in early study

explore

hotspot

hotspot

focus